UPDATE 2-U.S. FDA approves AbbVie hepatitis C drug, costs $83,319 for 12 weeks

Dec 19 (Reuters) - U.S. health regulators on Friday approved AbbVie's all-oral treatment for hepatitis C, and the company said the drug would cost $83,319 for a typical 12-week plan, a bit below its huge selling competitor Solvadi from Gilead Sciences.